10-Q: Crinetics Advances Key Programs, Reports Increased Loss

Crinetics Pharmaceuticals reports increased losses driven by accelerated R&D and commercialization efforts, while advancing its lead drug candidates Paltusotine and Atumelnant with positive clinical and regulatory updates.

Summary

• Crinetics Pharmaceuticals, a clinical-stage company, reported a net loss of $115.6 million for Q2 2025, up 56% from $74.1 million in Q2 2024, and $212.4 million for the six months ended June 30, 2025, up 51% from $141.0 million in the prior year period.
• Revenues increased significantly to $1.0 million in Q2 2025 from $0.4 million in Q2 2024, and to $1.4 million for the six months ended June 30, 2025, from $1.0 million in the prior year, primarily from the Sanwa License and Clinical Supply Agreement.
• Research and development (R&D) expenses rose 38% to $80.3 million in Q2 2025 and 40% to $156.5 million for the six months ended June 30, 2025, driven by increased headcount, manufacturing, and clinical costs for advancing programs like Paltusotine and Atumelnant.
• Selling, general and administrative (SG&A) expenses more than doubled to $49.8 million in Q2 2025 and increased 87% to $85.4 million for the six months ended June 30, 2025, due to higher personnel costs and pre-commercialization activities for PALSONIFY™.
• Net cash used in operating activities increased 73% to $174.3 million for the six months ended June 30, 2025, compared to $100.5 million in the same period last year.
• As of June 30, 2025, the company held $1.2 billion in cash, cash equivalents, and investment securities, down from $1.35 billion at December 31, 2024.
• The U.S. FDA review for PALSONIFY™ (paltusotine) for acromegaly continues as expected, with a Prescription Drug User Fee Act (PDUFA) Target Action Date of September 25, 2025.
• The European Medicines Agency (EMA) validated the Marketing Authorization Application (MAA) for paltusotine for acromegaly, with a potential EMA decision in the first half of 2026, and granted Orphan Drug Designation.
• Positive Phase 2 TouCAHn open-label study results for atumelnant in congenital adrenal hyperplasia (CAH) showed rapid, substantial, and sustained statistically significant reduction in A4 levels, with good tolerability and clinical improvements.
• The company announced plans to initiate the BALANCE-CAH pediatric study in the second half of 2025 and the Phase 2/3 trial of atumelnant in ACTH-Dependent Cushing's Syndrome (ADCS) in the first half of 2026.
• Investigational New Drug (IND) clearance was received for CRN09682, the first candidate from the nonpeptide drug conjugate (NDC) platform, with a Phase 1/2 study initiated for neuroendocrine and other SST2-expressing solid tumors.
• Preclinical data for CRN12755 (TSH antagonist for Graves disease) and CRN10329 (SST3 agonist for ADPKD) were revealed, showing promising results in relevant disease models.
• The company maintains a 25% ownership in Radionetics Oncology, Inc., which formed a strategic partnership with Eli Lilly and Company in July 2024, including a $140 million upfront payment and an exclusive right for Lilly to acquire Radionetics for $1.0 billion. Crinetics is eligible for potential sales milestones exceeding $300.0 million and single-digit royalties.

Sentiment

Score: 7

Explanation: The company demonstrates strong clinical and regulatory progress across its pipeline, particularly with Paltusotine nearing a PDUFA date and positive Phase 2 data for Atumelnant. The strategic partnership involving Radionetics is also a significant positive. However, the substantial and increasing net losses and cash burn, while expected for a clinical-stage biotech, represent a financial negative. The company's strong cash position provides a buffer, but future capital raises are anticipated.

Positives

• Paltusotine's U.S. FDA review for acromegaly continues as expected, with a PDUFA Target Action Date of September 25, 2025, indicating a clear regulatory pathway.
• The European Medicines Agency (EMA) validated the Marketing Authorization Application (MAA) for paltusotine and granted Orphan Drug Designation, highlighting unmet medical need and market potential in Europe.
• Atumelnant's Phase 2 TouCAHn study in CAH reported positive results, demonstrating rapid, substantial, and sustained statistically significant reduction in A4 levels, good tolerability, and significant clinical improvements.
• Advancement of atumelnant into a Phase 3 CALM-CAH study with an uncompromising primary endpoint to normalize A4 levels, signaling confidence in its potential.
• Initiation of the BALANCE-CAH pediatric study in H2 2025 and planned initiation of the Phase 2/3 trial for atumelnant in ADCS in H1 2026 expands the clinical pipeline.
• IND clearance for CRN09682 and initiation of its Phase 1/2 study marks the first candidate from the novel nonpeptide drug conjugate (NDC) platform, diversifying the pipeline.
• Promising preclinical data for CRN12755 (Graves disease) and CRN10329 (ADPKD) indicate a robust early-stage pipeline with potential for future value creation.
• The strategic partnership between Radionetics Oncology (25% owned by Crinetics) and Eli Lilly, including a $140 million upfront payment and a $1.0 billion acquisition option, validates Crinetics' radiotherapeutics technology and offers significant potential future milestones and royalties (over $300 million in sales milestones).
• Strong cash, cash equivalents, and investment securities balance of $1.2 billion as of June 30, 2025, provides sufficient liquidity for at least the next 12 months of operations.

Negatives

• Net loss increased significantly by 56% to $115.6 million in Q2 2025 and 51% to $212.4 million for the six months ended June 30, 2025, indicating a substantial increase in cash burn.
• Net cash used in operating activities increased by 73% to $174.3 million for the six months ended June 30, 2025, reflecting accelerated spending without corresponding product revenue.
• Selling, general and administrative (SG&A) expenses more than doubled in Q2 2025 and increased 87% for the six-month period, indicating high costs associated with pre-commercialization activities for a product not yet approved.
• The company has an accumulated deficit of $1.2 billion as of June 30, 2025, and expects to continue incurring net losses for the foreseeable future.
• The company believes it may need to raise substantial additional capital over the next several years, which could lead to shareholder dilution if equity offerings are pursued.

Risks

• The company has a limited operating history and its sales and income potential are unproven, with no products approved for sale and no product sales generated to date.
• Successful transition to profitable operations is dependent upon achieving a level of revenues adequate to support the company's cost structure, which is uncertain.
• The company expects to continue to incur net losses for the foreseeable future and may need to raise substantial additional capital, which may not be available on favorable terms or at all.
• Failure to secure adequate additional funding could force the company to make reductions in spending, extend payment terms, liquidate assets, or suspend/curtail planned programs, materially harming the business.
• The process of testing product candidates in clinical trials is costly, and the timing of progress and expenses is uncertain, with clinical and preclinical development timelines, probability of success, and costs differing materially from expectations.
• Future capital requirements depend on many factors, including the type, number, scope, progress, results, costs, and timing of preclinical studies and clinical trials, manufacturing costs, regulatory review, and commercialization efforts.
• Raising additional capital through equity or convertible debt securities will or could dilute the ownership interest of existing stockholders.
• Debt financing and preferred equity financing, if available, may involve agreements with covenants limiting the company's ability to take specific actions.
• If funds are raised through collaborations or licenses, the company may have to relinquish valuable rights to technologies, future revenue streams, or product candidates on unfavorable terms.
• The company's ability to access financing may be impacted by volatility in global credit and financial markets, including inflation, rising interest rates, and currency fluctuations.
• The company's investment in Radionetics Oncology, Inc. is accounted for under the equity method, and the investment asset was previously written down to zero, indicating past impairment.

Future Outlook

The company expects to continue to incur net losses for the foreseeable future as it conducts ongoing and planned clinical trials, continues research and development activities, hires additional personnel, protects intellectual property, and incurs costs associated with being a public company. It anticipates increasing research and development expenses for the foreseeable future. The company believes its existing capital resources, along with income from investment securities, will be sufficient for at least the next 12 months, but expects to need substantial additional capital over the next several years, planning to fund through equity offerings, debt financings, or collaborations. The company plans to initiate the BALANCE-CAH pediatric study in the second half of 2025 and the Phase 2/3 trial of atumelnant in ADCS in the first half of 2026. Data from Cohort 4 of the adult Phase 2 atumelnant study is expected early in 2026. A potential EMA decision for paltusotine is anticipated in the first half of 2026, following the U.S. FDA PDUFA Target Action Date of September 25, 2025.

Management Comments

• Our vision is to build the premier, endocrine-rooted global pharmaceutical company dedicated to improving the lives of patients.
• Paltusotine U.S. Food and Drug Administration review of PALSONIFY for the treatment and maintenance of acromegaly continues as expected.
• Our research suggests that there are approximately 11,000 addressable patients, approximately 500 newly diagnosed addressable patients each year and at least 17,000 undiagnosed patients in the U.S. for acromegaly.
• Atumelnant administration was shown to result in rapid, substantial and sustained statistically significant reduction in androstenedione (A4) levels, the key biomarker for disease control. Atumelnant was well-tolerated and demonstrated significant clinical improvements.
• The Phase 3 CALM-CAH study is designed with an uncompromising primary endpoint to demonstrate atumelnant's potential ability to normalize A4 levels with physiological glucocorticoid (GC) replacement.
• We plan to initiate the BALANCE-CAH pediatric study in the second half of 2025.
• We expect to initiate the Phase 2/3 trial of atumelnant in ADCS in the first half of 2026.
• We do not expect to generate any revenues from product sales unless and until we successfully obtain regulatory approval for one or more of our product candidates.

Industry Context

Crinetics Pharmaceuticals operates in the highly competitive and capital-intensive clinical-stage pharmaceutical sector, specifically targeting endocrine diseases and endocrine-related tumors. The company's focus on G protein coupled receptors (GPCRs) for nonpeptide small molecule therapeutics positions it within a specialized niche. The advancement of multiple candidates (Paltusotine, Atumelnant, CRN09682, CRN12755, CRN10329) through various clinical and preclinical stages is typical for a biotech aiming to build a robust pipeline. The significant increase in R&D and SG&A expenses reflects the high costs associated with late-stage clinical development and pre-commercialization activities, which are standard for companies approaching potential market entry. The strategic partnership of its equity investment, Radionetics, with Eli Lilly, underscores the value of radiotherapeutics and highlights the potential for non-dilutive revenue streams through collaborations, a common strategy in the biotech industry to offset high development costs.

Comparison to Industry Standards

• The company's cash burn rate, with net cash used in operating activities increasing 73% to $174.3 million for the six months ended June 30, 2025, is high but typical for a clinical-stage pharmaceutical company with multiple programs advancing, especially with a lead candidate (Paltusotine) under FDA review and another (Atumelnant) entering Phase 3.
• The reported 158% increase in revenue for Q2 2025, while small in absolute terms ($1.0 million), is positive for a company without product sales, indicating successful licensing and supply agreements, which is a common early-stage revenue source in biotech.
• The significant increase in R&D (40% for 6M 2025) and SG&A (87% for 6M 2025) expenses is consistent with industry trends for companies investing heavily in late-stage clinical trials and building commercial infrastructure ahead of potential product launches, such as for PALSONIFY™.
• The PDUFA Target Action Date of September 25, 2025, for PALSONIFY™ is a critical near-term catalyst, comparable to similar regulatory milestones for other biotech companies awaiting first product approvals.
• The positive Phase 2 data for Atumelnant in CAH, showing statistically significant reduction in A4 levels, positions it favorably against other potential treatments for rare endocrine disorders, where unmet needs are high.
• The strategic partnership between Radionetics Oncology (partially owned by Crinetics) and Eli Lilly, involving a $140 million upfront payment and a $1.0 billion acquisition option, is a strong validation of the underlying technology and a significant non-dilutive value driver, comparable to major pharma-biotech collaborations seen across the industry.

Legal Proceedings

• Not currently a party to any material legal proceedings. From time to time, the company may be subject to various claims and suits arising in the ordinary course of business, but does not expect them to have a material adverse effect on financial position or results of operations.

Related Party Transactions

• R. Scott Struthers, Ph.D., the company's President and Chief Executive Officer, serves as chairman of the Radionetics board of directors, receiving consideration in the form of equity and a $50,000 annual retainer. As of June 30, 2025, Dr. Struthers has an approximately 1.3% ownership stake in Radionetics.

Stakeholder Impact

• Shareholders face potential future dilution due to anticipated capital raises, but also stand to benefit from potential product approvals and milestone payments from collaborations like the Radionetics/Lilly partnership.
• Patients suffering from endocrine diseases (acromegaly, CAH, ADCS, Graves disease, ADPKD) and neuroendocrine tumors could benefit from the advancement of multiple product candidates, particularly with Paltusotine nearing potential approval.
• Employees are impacted by increased headcount and stock-based compensation, reflecting company growth and investment in its workforce.
• Creditors and suppliers may face extended payment terms if the company is unable to secure adequate additional funding, though current liquidity appears strong for the near term.

Next Steps

• U.S. FDA decision on PALSONIFY™ (paltusotine) for acromegaly by September 25, 2025 (PDUFA Target Action Date).
• Potential EMA decision for paltusotine for acromegaly in the first half of 2026.
• Initiation of the BALANCE-CAH pediatric study for atumelnant in the second half of 2025.
• Expected data from enrollment completion of Cohort 4 of the adult Phase 2 study for atumelnant early in 2026.
• Initiation of the Phase 2/3 trial of atumelnant in ACTH-Dependent Cushing's Syndrome (ADCS) in the first half of 2026.
• Continued progress on the Phase 1/2 dose escalation study of CRN09682 for metastatic or locally advanced SST2-positive neuroendocrine tumors and other SST2-expressing solid tumors.

Key Dates

Recommendation

Despite increasing net losses and cash burn, which are typical for a clinical-stage biotech, Crinetics Pharmaceuticals demonstrates significant progress across its pipeline. The upcoming PDUFA date for PALSONIFY™ in September 2025 is a major near-term catalyst. Positive Phase 2 data for Atumelnant and the advancement of multiple early-stage programs indicate a robust and diversified pipeline. The strategic partnership between Radionetics (in which Crinetics holds a 25% stake) and Eli Lilly provides a strong validation of Crinetics' technology and a potential future revenue stream from milestones and royalties. The company's substantial cash reserves of $1.2 billion provide a strong financial runway for at least the next 12 months, mitigating immediate liquidity concerns. The increased expenses reflect necessary investments in late-stage development and pre-commercialization, positioning the company for potential future growth and profitability upon product approvals. This filing suggests strong operational execution and significant value creation potential, making it an attractive 'buy' for investors with a long-term view on biotech.

Keywords

Crinetics Pharmaceuticals, Paltusotine, PALSONIFY, Acromegaly, Atumelnant, Congenital Adrenal Hyperplasia, ACTH-Dependent Cushing's Syndrome, CRN09682, Neuroendocrine Tumors, CRN12755, Graves Disease, CRN10329, Autosomal Dominant Polycystic Kidney Disease, Clinical-stage pharmaceutical, Endocrine diseases, SEC filing, 10-Q, Biotechnology, Drug development, FDA review, EMA validation, Orphan Drug Designation, Clinical trials, Preclinical studies, Cash burn, Liquidity, Capital raise, Radionetics Oncology, Eli Lilly, Partnership, Royalties, Milestone payments